• 5752 Citations
  • 39 h-Index
1979 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Chronic Obstructive Pulmonary Disease Medicine & Life Sciences
Bronchodilator Agents Medicine & Life Sciences
Safety Medicine & Life Sciences
Asthma Medicine & Life Sciences
Lung Medicine & Life Sciences
Placebos Medicine & Life Sciences
Forced Expiratory Volume Medicine & Life Sciences
Metered Dose Inhalers Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2000 2015

Research Output 1979 2018

Chronic Obstructive Pulmonary Disease
Guidelines
Patient Care
History
Therapeutics
2 Citations

Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease

Donohue, J. F., Jones, P. W., Bartels, C., Marvel, J., D'Andrea, P., Banerji, D., Morris, D. G., Patalano, F. & Fogel, R., Apr 1 2018, In : Pulmonary Pharmacology and Therapeutics. 49, p. 11-19 9 p.

Research output: Contribution to journalReview article

Pulmonary diseases
Chronic Obstructive Pulmonary Disease
Clinical Trials
Dyspnea
Muscarinic Antagonists

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: Results from a 52-week trial

Donohue, J. F., Bollu, V. K., Stull, D. E., Nelson, L. M., Williams, V. S., Stensland, M. D. & Hanania, N. A., Feb 5 2018, In : International Journal of COPD. 13, p. 499-508 10 p.

Research output: Contribution to journalArticle

Chronic Obstructive Pulmonary Disease
Quality of Life
Placebos
Forced Expiratory Volume
Dyspnea
8 Citations
Chronic Obstructive Pulmonary Disease
Placebos
Safety
Health Status
Nasopharyngitis
16 Citations

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Reisner, C., Fabbri, L. M., Kerwin, E. M., Fogarty, C., Spangenthal, S., Rabe, K. F., Ferguson, G. T., Martinez, F. J., Donohue, J. F., Darken, P., St Rose, E., Orevillo, C., Strom, S., Fischer, T., Golden, M. & Dwivedi, S., Jan 6 2017, In : Respiratory Research. 18, 1, 8.

Research output: Contribution to journalArticle

Glycopyrrolate
Metered Dose Inhalers
Chronic Obstructive Pulmonary Disease
Suspensions
Technology